FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 微泰醫療器械（杭州）股份有限公司（於中華人民共和國註冊成立） | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年3月31日 | 165,498,142 | | 3,677,700 | | 169,175,842 | | 1). ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 微泰醫療器械（杭州）股份有限公司（於中華人民共和國註冊成立） 呈交日期： 2026年3月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致的任何損失承擔任何責任。 MicroTech Medical (Hangzhou) Co., Ltd. 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 截至2025年12月31日止年度的年度業績公告 董事會欣然宣佈本集團截至2025年12月31日止年度的經審核合併年度業績，連 同截至2024年12月31日止年度的比較數字。 財務摘要 截至2025年12月31日止年度，本集團錄得以下年度業績： | | 截至2025年 | 截至2024年 | | | --- | --- | --- | --- | | | 12月31日止 | 12月31日止 | | | | 年度 | 年度 | 同比變動 | | | 人民幣元 | 人民幣元 | % | | 營業收入 | 660,788,390.77 | 345,615,086.92 | ...

Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly focusing on those with promising pipelines and market potential [14]. Core Insights - The innovative drug sector in China is experiencing high-quality growth in research and development, significantly outpacing global averages. This trend positions China as a key player in the global innovative drug market [10]. - The medical device sector is seeing a recovery in bidding scales and a shift towards innovation, with companies like Mindray Medical and Aohua Endoscopy being highlighted for their growth potential [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like BGI Genomics and Nanwei Technology being recommended for investment [17]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being noted as key players [18]. Summary by Sections Market Review - The medical index rose by 1.49%, outperforming the CSI 300 index by 2.9 percentage points, ranking fifth among 30 sectors [7]. - Top-performing stocks included Meinuohua and Wanbangde, while stocks like Keyuan Pharmaceutical and Changyao Tui faced significant declines [30]. Innovative Drugs - The report emphasizes the importance of innovative drugs, with a focus on companies like BeiGene and Hengrui Medicine, which are expected to benefit from global market expansion [10][14]. - The collaboration between companies like JAK-23E73 and AstraZeneca is highlighted as a significant advancement in the innovative drug pipeline [14]. Medical Devices - The report notes a recovery in the medical device sector, with a focus on high-value consumables and the internationalization of domestic companies [15]. - Companies such as Mindray Medical and Aohua Endoscopy are recommended for their innovative products and growth potential in both domestic and international markets [15]. Life Sciences Services - The life sciences service sector is expected to see a recovery in demand, with companies like BGI Genomics and Bioplus being highlighted for their growth potential [17]. - The report indicates that the sector's profitability is expected to improve as revenue growth resumes [17]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being recommended for investment [18]. - The report suggests that the integration of online and offline pharmacy services will enhance competitiveness [18]. Traditional Chinese Medicine - The report highlights the potential for growth in traditional Chinese medicine, particularly in basic drug categories and state-owned enterprise reforms [21]. - Companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical are recommended for their strong market positions [21]. Medical Services - The report suggests that the medical services sector will benefit from anti-corruption measures and the expansion of private healthcare, with companies like Gushengtang and Aier Eye Hospital being noted for their growth potential [20]. Blood Products - The report indicates that the blood products sector is expected to see growth due to relaxed approval processes and increasing demand, with companies like Tiantan Biological Products being highlighted [12].

微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 微泰醫療器械（杭州）股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 本公司將於2026年3月30日（星期一）舉行董事會會議，其中包括審議及批准本 公司及其附屬公司截至2025年12月31日止年度之全年業績及其發佈，並考慮建 議派發末期股息（如有）。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 微泰醫療器械（杭州）股份有限公司 MicroTech Medical (Hangzhou) Co., Ltd. 董事會會議召開日期 鄭攀 中國，杭州，2026年3月18日 於本公告日期，本公司執行董事為鄭攀博士、于非博士、施永輝博士及劉秀女士；本公司非 執行董事為毛碩先生及高韻女士；及本公司獨立非執行董事為厲力華博士、王春鳳女士、何 建昌先生及程華博士。 董事長 ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides various investment recommendations for specific companies within the sector. Core Insights - The report highlights the rapid growth of the electrophysiology industry, driven by an increasing number of patients with rapid arrhythmias and advancements in medical technology. The market for electrophysiology devices is expected to expand significantly due to rising demand and improved penetration rates of innovative products [11][21]. Summary by Sections Market Overview - The global electrophysiology device market is projected to grow from $7.9 billion in 2025 to $20.1 billion by 2034, with a CAGR of 11.0%. In China, the market is expected to increase from ¥15.7 billion in 2025 to ¥42 billion by 2032, with a CAGR of 15.1% [21][22]. Key Industry Trends - The report identifies several key trends in the electrophysiology market: 1. Increasing prevalence of rapid arrhythmias, with an estimated 28.2 million patients in China by 2024 [16]. 2. The adoption of catheter ablation as the first-line treatment for rapid arrhythmias due to its effectiveness and minimal invasiveness [16]. 3. The ongoing shift towards domestic production in the electrophysiology device market, with local companies making significant technological advancements [22]. Company Recommendations - The report suggests focusing on specific companies within the electrophysiology sector: 1. For electrophysiology mapping products, companies like 惠泰医疗 (Huitai Medical), 微电生理 (Micro Electrophysiology), and 锦江电子 (Jinjiang Electronics) are highlighted for their innovative technologies and market potential [22]. 2. In the radiofrequency ablation segment, major players include Johnson & Johnson, Abbott, and Medtronic, with a focus on their advanced product offerings [30]. 3. The report also emphasizes the potential of pulse field ablation (PFA) technology, with companies like 锦江电子 (Jinjiang Electronics) leading in this area [39]. Technological Innovations - The report discusses several technological advancements in the electrophysiology field: 1. The introduction of AI-assisted mapping and ablation technologies that enhance procedural efficiency and accuracy [27]. 2. The development of multi-modal integration techniques that combine mapping, ablation, and verification in a single catheter [39]. 3. Innovations in cryoablation and radiofrequency systems that improve patient safety and treatment outcomes [36][30]. Regulatory Landscape - The report notes that the approval process for electrophysiology devices has seen a slowdown in recent years, but the proportion of domestic products has been increasing, indicating a shift towards local manufacturing and innovation [27][36].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微泰醫療器械（杭州）股份有限公司 (於中華人民共和國注冊成立) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02235 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 169,175,842 | RMB | | 1 RMB | | 169,175,842 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 169,175,842 | RMB | | 1 RMB | | 169,175,842 | | 2. 股份分類 | 普通股 | ...

Investment Rating - The report maintains a "Strong Buy" rating for Weitai Medical-B (02235.HK) [1] Core Views - The company recently announced a positive earnings forecast for 2025, projecting revenue of no less than 650 million yuan, representing a year-on-year growth of approximately 88.1%, and achieving a net profit of no less than 38 million yuan, reversing a loss of 63 million yuan in the same period last year [1] - Revenue growth is primarily driven by strong performance in core products, particularly Continuous Glucose Monitoring (CGM) systems, and significant expansion in overseas markets [6] - The company has successfully entered multiple countries with its LinX CGM system, leading to substantial international revenue growth [6] - The company is expected to continue high growth in overseas markets in 2026, with recent approvals in populous countries like India and Brazil [6] - The closed-loop artificial pancreas is anticipated to receive approval in 2026, which will enhance the company's diabetes management product portfolio [6] - The target market capitalization is set at 5.9 billion HKD, corresponding to a target price of 14.0 HKD per share, based on a 4x PS valuation for the main business [6] Financial Summary - Total revenue projections for 2025-2027 are 651 million, 882 million, and 1,161 million yuan, with year-on-year growth rates of 88.3%, 35.6%, and 31.6% respectively [6] - Net profit projections for the same period are 38 million, 93 million, and 152 million yuan, with year-on-year growth rates of 160.7%, 143.2%, and 63.5% respectively [6] - The company has a total market capitalization of 3.196 billion HKD and a circulating market value of 1.257 billion HKD [3]

Investment Rating - The report maintains a "Strong Buy" rating for Weitai Medical-B (02235.HK) [1] Core Views - The company recently announced a positive earnings forecast for 2025, projecting revenue of no less than 650 million yuan, representing a year-on-year growth of approximately 88.1%, and achieving a net profit of no less than 38 million yuan, reversing a loss of 63 million yuan in the same period last year [1] - Revenue growth is primarily driven by strong performance in core products, particularly Continuous Glucose Monitoring (CGM) systems, and significant expansion in overseas markets [6] - The company has successfully entered multiple countries with its LinX CGM system, leading to substantial international revenue growth [6] - The company is expected to continue high growth in overseas markets in 2026, with recent approvals in populous countries like India and Brazil [6] - The closed-loop artificial pancreas is anticipated to receive approval in 2026, which will enhance the company's diabetes management product portfolio [6] - The target market capitalization is set at 5.9 billion HKD, corresponding to a target price of 14.0 HKD per share, based on a 4x PS valuation for the main business [6] Financial Summary - For the fiscal years 2024A to 2027E, the projected total revenue is as follows: - 2024A: 346 million yuan - 2025E: 651 million yuan - 2026E: 882 million yuan - 2027E: 1,161 million yuan - Year-on-year growth rates for total revenue are projected at 36.5%, 88.3%, 35.6%, and 31.6% respectively [1][7] - The net profit forecast for the same period is: - 2024A: -63 million yuan - 2025E: 38 million yuan - 2026E: 93 million yuan - 2027E: 152 million yuan - Year-on-year growth rates for net profit are projected at 49.5%, 160.7%, 143.2%, and 63.5% respectively [1][7] - The company’s earnings per share (EPS) is expected to improve from -0.15 yuan in 2024A to 0.36 yuan in 2027E [1][7]

Core Viewpoint - The Hong Kong and A-share markets are experiencing positive trends, with the medical device sector showing signs of recovery, particularly in the context of policy optimization and inventory reduction. MicroTech Medical (02235.HK) has reported significant revenue growth and a return to profitability, driven by strong CGM sales, overseas market expansion, and improved operational efficiency [1][12]. Group 1: Market Trends and Opportunities - The medical device sector is benefiting from favorable market conditions, with a bullish outlook for the industry as a whole [1]. - The global diabetes patient population is projected to exceed 589 million in 2024, with China leading in numbers, indicating a growing market for diabetes management solutions [4]. - Continuous Glucose Monitoring (CGM) technology is transforming blood sugar management, offering real-time data and improving patient experiences compared to traditional methods [5]. Group 2: Company Performance and Growth - MicroTech Medical's revenue for 2025 is expected to reach at least 650 million yuan, representing an approximate 88.1% year-on-year increase, with a net profit of over 38 million yuan [12]. - The company has seen robust growth in its core CGM product, with significant international market expansion contributing to its revenue increase [12]. - The reduction in sales and management expenses has improved profitability, marking a transition from a strategic loss phase to a profit-driven growth stage [12]. Group 3: Strategic Advantages - MicroTech Medical is uniquely positioned with a comprehensive product lineup, including both a patch insulin pump and a real-time CGM, providing a full spectrum solution for diabetes management [16]. - The company is exploring AI applications in CGM, enhancing personalized health management services through data analysis [17]. - The increasing share of overseas revenue demonstrates the company's global market capabilities, with potential for further growth in emerging markets [18]. Group 4: Market Valuation and Future Outlook - The recent performance forecast is expected to catalyze a revaluation of MicroTech Medical's stock, supported by its unique product offerings and global growth potential [20]. - Leading brokerages have expressed optimistic views on the company's future, with target prices indicating significant undervaluation compared to global peers [20].